Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 12:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1585–1608 of 16,128 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Skin Disorder Clear all

Conditions: Breast Cancer
Interventions: Ovarian Function Suppression + Aromatase Inhibitor, Adjuvant Chemotherapy + Ovarian Function Suppression; Drug
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 3,960 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2034
U.S. locations: 1226
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 809 more

Conditions: Melanoma
Interventions: Talimogene Laherparepvec, Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF); Biological · Drug
Lead sponsor: BioVex Limited; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 9
States / cities: Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 6 more

Conditions: Lymphedema
Interventions: quality of life assessment, educational intervention, Physical therapy; Other · Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2017
U.S. locations: 76
States / cities: Castro Valley, California • Concord, California • Fremont, California + 58 more

Conditions: Systemic Lupus Erythematosus
Interventions: Telitacicept, Placebo; Biological
Lead sponsor: Vor Biopharma; Industry
Eligibility: 12 Years to 70 Years
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 12
States / cities: Anniston, Alabama • Mission Hills, California • Orange, California + 9 more

Conditions: MPO-ANCA Vasculitis, Microscopic Polyangiitis
Interventions: CellCept (mycophenolate mofetil); Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Lupus Nephritis
Interventions: Obinutuzumab, MMF, Prednisone, Placebo, Methylprednisolone, Acetaminophen, Diphenhydramine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 271 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2031
U.S. locations: 18
States / cities: Birmingham, Alabama • Beverly Hills, California • Fontana, California + 14 more

Conditions: Triple Negative Breast Cancer
Interventions: Olaparib Oral Product, Olaparib Oral Product in combination with Durvalumab; Drug
Lead sponsor: Duke University; Other
Eligibility: 21 Years and older · Female only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Breast Cancer
Interventions: therapeutic autologous dendritic cells, conventional surgery, neoadjuvant therapy; Biological · Procedure
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Cancer
Interventions: nab-paclitaxel, Bevacizumab, Trastuzumab; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older · Female only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 6
States / cities: Fort Myers, Florida • Orlando, Florida • Gainesville, Georgia + 3 more

Conditions: Inflammation, Cancer, Pain, Hypertension
Interventions: Sulindac; Drug
Lead sponsor: Stony Brook University; Other
Eligibility: Up to 75 Years · Female only
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 2
States / cities: Tucson, Arizona • Stony Brook, New York

Conditions: Keloid Scar
Interventions: Scripted lecture ("educational information talk"); Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Breast Cancer, Lymphedema
Interventions: Kinect-TOLF Training System; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 21 Years to 90 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Atopic Dermatitis
Interventions: GIA632, Placebo; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Fremont, California • Rockville, Maryland • Hoboken, New Jersey

Conditions: Systemic Lupus Erythematosus, COVID-19
Interventions: LEAP Education + Navigation, LEAP Education; Behavioral
Lead sponsor: Tulane University; Other
Eligibility: 18 Years and older
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Irritable Bowel Syndrome
Interventions: DDP225; Drug
Lead sponsor: Dynogen Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 5
States / cities: Scottsdale, Arizona • St Louis, Missouri • Great Neck, New York + 2 more

Conditions: Fatigue, Breast Cancer, Cancer, Therapy-Related
Interventions: Center-Based Walking Exercise, Home-Based Walking Exercise; Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 60 Years to 105 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Metastatic Breast Cancer
Interventions: biomarker study; Other
Lead sponsor: Side-Out Foundation; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 8
States / cities: Birmingham, Alabama • Los Angeles, California • Miami, Florida + 4 more

Conditions: Advanced/Metastatic HER2-negative Breast Cancer
Interventions: No drug; Other
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 1,415 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer
Interventions: In-person education, E-communication, Control; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 21 Years and older · Female only
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Spontaneous Urticaria (CSU), Chronic Idiopathic Urticaria
Interventions: THB335 Lower Dose, THB335 Higher Dose, Placebo; Drug
Lead sponsor: Calixis Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 15
States / cities: Pasadena, California • Ventura, California • Walnut Creek, California + 12 more

Conditions: Rheumatoid Arthritis
Interventions: Rituximab; Biological
Lead sponsor: Gaylis, Norman B., M.D.; Individual
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 6
States / cities: Fort Lauderdale, Florida • Hollywood, Florida • Miami, Florida + 2 more

Conditions: Brain and Central Nervous System Tumors, Melanoma, Solid Tumor
Interventions: PS-341 (VELCADE), Temozolomide, immunoenzyme technique; Drug · Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Atopic Dermatitis, Pruritus, Sleep Disturbance
Interventions: Not listed
Lead sponsor: University of Rochester; Other
Eligibility: 12 Years to 75 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Estrogen Receptor Status, HER2/Neu Negative, Invasive Breast Carcinoma, Postmenopausal, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions: Alisertib, Fulvestrant, Laboratory Biomarker Analysis; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 8
States / cities: Washington D.C., District of Columbia • Boston, Massachusetts • Ann Arbor, Michigan + 5 more

Search by objective public record fields.

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma

Education With or Without Exercise and Counseling in Preventing Lymphedema in Women With Stage I, Stage II, or Stage III Breast Cancer Who Are Undergoing Axillary Lymph Node Dissection

A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)

CellCept in p-ANCA Vasculitis

A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis

Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA)

Vaccine Therapy in Treating Patients Who Are Undergoing Surgery for Ductal Carcinoma In Situ of the Breast

Preoperative Bevacizumab and Trastuzumab With ABI-007 and Carboplatin in HER2+ Breast Cancer

NSAID Effects on Clinical and Imaging Breast Biomarkers

Assessing and Improving Patient Knowledge About Keloid Scars (Keloids)

Pilot Usability and Feasibility Testing on Kinect-Enhanced Training System for Lymphatic Exercises

Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis

Lupus Education Alliance Program

8 Weeks Treatment With DDP225 in Patients With Diarrhea Predominant IBS

Exercise to ReGain Stamina and Energy (The EXERGISE Study)

Utilizing Multiomic Advanced Diagnostics to Identify CDK 4/6 Inhibitor Response Predictors and a Post-treatment Multiomic Signature for Patients With ER+/HER2- Metastatic Breast Cancer

Real-World Outcomes of Patients With Metastatic Breast Cancer After Treatment With First-Line ET+CDK4/6i

Diet and Physical Activity Changes Among Latina Breast Cancer Survivors

A Study to Assess the Efficacy and Safety of THB335 in Adults With Chronic Spontaneous Urticaria (CSU)

Impact of Rituximab on MRI Evidence of Disease Activity in Patients With Moderate to Severe Rheumatoid Arthritis

Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma

Scratch and Sleep Quantification in Atopic Dermatitis

Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer